(October 29, 2015, 1:01 PM EDT) -- WASHINGTON, D.C. — Apotex Inc. argues in an Oct. 5 opposition brief that the U.S. Supreme Court should not review a drug patent infringement lawsuit over efforts to end a company’s generic exclusivity for the “Benicar” hypertension drug through a noninfringement decision (Daiichi Sankyo, Inc. and Daiichi Sankyo Co., Ltd. v. Apotex, Inc.; Mylan Pharmaceuticals, Inc. v. Apotex, Inc., Nos. 15-281, 15-307, U.S. Sup.).

(Respondent’s opposition brief available. Document #78-151102-005B.)

On March 31, the Federal Circuit U.S. Court of Appeals ruled that a request by Apotex...